Tan E - Search Results

1

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).

Infante JR, Ramanathan RK, George D, Tan E, Quinlan M, Liu A, Scott JW, Sharma S. Infante JR, et al. Among authors: tan e. Cancer Chemother Pharmacol. 2015 Apr;75(4):729-37. doi: 10.1007/s00280-015-2681-3. Epub 2015 Feb 4. Cancer Chemother Pharmacol. 2015. PMID: 25648347 Clinical Trial.

2

Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.

Dubbelman AC, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JH. Dubbelman AC, et al. Among authors: tan e. Cancer Chemother Pharmacol. 2012 Nov;70(5):653-63. doi: 10.1007/s00280-012-1947-2. Epub 2012 Aug 22. Cancer Chemother Pharmacol. 2012. PMID: 23010851 Clinical Trial.

3

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.

Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Sarantopoulos J, et al. Among authors: tan e. Cancer Chemother Pharmacol. 2016 Nov;78(5):921-927. doi: 10.1007/s00280-016-3122-7. Epub 2016 Sep 28. Cancer Chemother Pharmacol. 2016. PMID: 27681579 Clinical Trial.

4

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. van Geel RMJM, et al. Among authors: tan e. Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31. Cancer Discov. 2017. PMID: 28363909 Free PMC article. Clinical Trial.

5

A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.

de Weger VA, Goel S, von Moos R, Schellens JHM, Mach N, Tan E, Anand S, Scott JW, Lassen U. de Weger VA, et al. Among authors: tan e. Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80. doi: 10.1007/s00280-017-3469-4. Epub 2017 Nov 3. Cancer Chemother Pharmacol. 2018. PMID: 29101463

6

Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs.

Ji Y, Tan E, Hengelage T, Quinlan M, Hendriks BS. Ji Y, et al. Among authors: tan e. Clin Pharmacol Ther. 2023 Aug;114(2):288-302. doi: 10.1002/cpt.2911. Epub 2023 May 26. Clin Pharmacol Ther. 2023. PMID: 37078098 Review.

7

Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.

Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. Tsimberidou AM, et al. Cancer Chemother Pharmacol. 2011 Dec;68(6):1507-16. doi: 10.1007/s00280-011-1635-7. Epub 2011 Apr 17. Cancer Chemother Pharmacol. 2011. PMID: 21499896 Clinical Trial.

8

Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.

Xia B, Heimbach T, Lin TH, He H, Wang Y, Tan E. Xia B, et al. Among authors: tan e. Cancer Chemother Pharmacol. 2012 Jun;69(6):1567-82. doi: 10.1007/s00280-012-1863-5. Epub 2012 Apr 11. Cancer Chemother Pharmacol. 2012. PMID: 22526410

9

Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.

Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Tsimberidou AM, et al. Among authors: tan e. Mol Cancer Ther. 2011 Jan;10(1):209-17. doi: 10.1158/1535-7163.MCT-10-0774. Mol Cancer Ther. 2011. PMID: 21220503 Clinical Trial.

10

Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature.

Tan EY, Chiparus O, Choudhury S, Kim C, Lau M, Ziltener C, Ilankumaran P. Tan EY, et al. Clin Pharmacol Drug Dev. 2022 Oct;11(10):1203-1210. doi: 10.1002/cpdd.1129. Epub 2022 Jun 23. Clin Pharmacol Drug Dev. 2022. PMID: 35736001 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,309 results

Search Page

Filters